MIT’s new ‘recursive’ framework lets LLMs process 10 million tokens without context rot

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Is Recursion Pharmaceuticals (RXRX) Pricing In Its AI Drug Discovery Ambitions?

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the market? This article walks through what the current numbers may be telling ...
The Walrus on MSNOpinion

Trump is the greatest hypnotist of our time

The ability to experience a common reality is being systematically dismantled The post Trump Is the Greatest Hypnotist of Our ...
The Motley Fool

Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Barron's

Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
pharmaphorum

Change at the top of Recursion as co-founder leaves CEO role

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Barron's

Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...